Vuky J, McCaffrey J, Ginsberg M, Mariani T, Bajorin D F, Bosl G J, Motzer R J
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Invest New Drugs. 2000 Aug;18(3):265-7. doi: 10.1023/a:1006434008357.
Thirteen patients with cisplatin-refractory germ cell tumors were treated on a Phase II trial with pyrazoloacridine. Pyrazoloacridine was given intravenously at 600 mg/m2 every three weeks. The median nadir leucocyte count was 2.5 cells/mm3, hemoglobin was 10.8 g/dl, and platelet count was 126,000 cells/m3. None of the thirteen evaluable patients achieved a major response. Pyrazoloacridine is not efficacious in the treatment of cisplatin-refractory germ cell tumors.
